Arvinas to Participate in Upcoming Investor Conferences
June 05 2023 - 6:00AM
Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology
company creating a new class of drugs based on targeted protein
degradation, today announced that management will participate in
two upcoming investor conferences:
- Jefferies Healthcare Conference on Thursday,
June 8. A live audio webcast of the fireside chat at 11 a.m. ET
will be available here and on the Events + Presentations section of
the Company’s website.
- Goldman Sachs 44th Annual Global Healthcare
Conference on Monday, June 12. A live audio webcast of the
fireside chat at 5:40 p.m. ET / 2:40 p.m. PT will be available here
and on the Events + Presentations section of the Company’s
website.
About ArvinasArvinas is a clinical-stage
biotechnology company dedicated to improving the lives of patients
suffering from debilitating and life-threatening diseases through
the discovery, development, and commercialization of therapies that
degrade disease-causing proteins. Arvinas uses its proprietary
PROTAC® Discovery Engine platform to engineer proteolysis
targeting chimeras, or PROTAC® targeted protein degraders,
that are designed to harness the body’s own natural protein
disposal system to selectively and efficiently degrade and remove
disease-causing proteins. In addition to its robust preclinical
pipeline of PROTAC® protein degraders against validated and
“undruggable” targets, the company has three investigational
clinical-stage programs in development: bavdegalutamide and ARV-766
for the treatment of men with metastatic castration-resistant
prostate cancer; and vepdegestrant (ARV-471) for the treatment of
patients with early and locally advanced or metastatic ER
positive/human epidermal growth factor receptor 2 (HER2) negative
(ER+/HER2-) breast cancer. For more information,
visit www.arvinas.com.
Contacts
Investors:Jeff Boyle+1 (347)
247-5089Jeff.Boyle@arvinas.com
Media:Kirsten Owens+1 (203)
584-0307Kirsten.Owens@arvinas.com
Arvinas (NASDAQ:ARVN)
Historical Stock Chart
From Apr 2024 to May 2024
Arvinas (NASDAQ:ARVN)
Historical Stock Chart
From May 2023 to May 2024